

QUality-of-life, Evaluation STudy



Curtin University

































What is the Global QUEST Initiative?

Little Green Pharma (LGP) is proudly supporting the world's largest medicinal cannabis Quality of Life (QoL) study conducted by researchers at Curtin University.

Primary outcomes are QoL and the health economic implications for patients accessing medicinal cannabis for chronic medical conditions.

QUEST PRESCIBER INFORMATION

What's involved?

- Study overview/training provided by researchers at Curtin University.
- Doctor completes a five-minute patient registration for eligible patients as part of the primary consult.
 - Medicinal cannabis prescribing to follow 'normal pathway'
 SAS B or Authorised Prescriber.
- Patients complete online questionnaires at the time of joining the study, and then again at 2 weeks and 1 month after starting medicinal cannabis therapy, 3 monthly for the rest of the first year then every 6 months until the end of the study.
- Minimal burden on the prescribing doctor.
 - Participants can 'opt-out' at any time.
 - Option for patients to participate for more than 12 months.
- Study Investigators:
 - A/Prof Richard Norman Principal Investigator
 - Mr Karl Gruber Research Officer

How will this benefit me and my patients?

- LGP will provide the LGP Classic medications at \$135.00 per unit (excluding LGP Classic 1:100 which is \$195 for 50mL) or \$130 per unit for a 10g sachet of flower including delivery fee.

 Current recommended retail cost per medication is from \$150-\$245.
- Opportunity to be part of a world-class QoL study conducted by researchers at a leading academic institution.
- Proposed launch date June 2023

^{*} Result will be published in relevant peer-reviewed journals

Prescriber Registration

Step 1

Prescriber registers with The QUEST Initiative

Please complete the online form at this URL: bit.ly/43ZQzpm (no 'www' required first)

© Step 2

Request education if required

If you would like education on medicinal cannabis or how to prescribe please contact Little Green Pharma on Ph: 1300 118 840, medical@lgpharma.com.au or register to the LGP Medical Portal at

https://portal.littlegreenpharma.com/medical-portal/register

© Step 3

Complete the short training

After receiving your completed online registration form, the Curtin University researchers will contact you directly and email your 30-minute online training videos and REDcap login link.

Patient Enrolment Requirements

Step 1

Patient books consultation

You can enrol any patients that are eligible to The Global QUEST Initiative, including your current patients.

Many patients will have assessed their potential eligibility via the Eligibility Quiz at thequestinitiative.com prior to their initial consultation.

Step 2

Enrol patient (if eligible)

Following a consultation, if the prescriber deems medicinal cannabis to be an appropriate treatment for their patient and they have determined that the patient would like to participate in The Global QUEST Initiative; the doctor will complete an online study registration form (15 Questions re: patient health information which should take approximately 5 minutes).

Patients will automatically receive a study invitation via email from the QUEST study researchers.

Step 3

Approval & script

Prescriber receives TGA SAS B or utilises AP approval and completes a script for the patient, ideally via escript and emails Oxford Compounding at quest@oxfordcompounding.com.au

Patient will be prompted to pay for their medication via a text message from Oxford Compounding Pharmacy.

The patient will be notified by text to arrange payment for their script prior to despatch of medication.

Step 4

Monitor patient

Follow-up as per routine standard of care as determine by each prescribing doctor.

If required, you will liaise directly with Curtin University researchers regarding any changes to your patient's participation on the QUEST study.

For more information & to register your interest

Please contact The Global QUEST Initiative team on 1300 664 369

or email medical@lgpharma.com.au

The ethical aspects of this study have been approved by the Human Research Ethics Committee of Curtin University HRE2022-0085.